-
Mashup Score: 15Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials - PubMed - 1 day(s) ago
SABR shows excellent long-term disease control for low- and intermediate-risk localized prostate cancer. Patients treated for prostate cancer have a moderate risk of SM, consistent with background rates for the population.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021–January 2022 - 1 month(s) ago
We aimed to estimate vaccine effectiveness (VE) against COVID-19 mortality, and to explore whether an increased risk of non-COVID-19 mortality exists in the weeks following a COVID-19 vaccine dose. National registries of causes of death, COVID-19 …
Source: pmc.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
That’s incredible news supporting the science of vaccines - 90% mortality reduction in 17y‼️ But don’t the #COVID19 vaccines deserve an honourable mention?!? 90% mortality reduction in 2 months. With a vaccine developed in less than 1 year‼️‼️ https://t.co/pJ9TAhL6fg https://t.co/uFuhHBguZb
-
-
Mashup Score: 1
We previously found no significant differences in mortality between men who underwent surgery for localized prostate cancer and those who were treated with observation only. Uncertainty persists re…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Interesting that Wilt’s #PIVOT study (RP vs WW for screen detected ds) with >19y mFU, there was no difference in OS or CSS. Maybe we need to wait 10 more years? https://t.co/1TTNnwMSuN https://t.co/Gj4lz0vvFb
-
-
Mashup Score: 32
This novel technique using standard linear accelerators seems feasible and is well tolerated. Further follow-up will be carried out to document late toxicity and efficacy.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
For the historians on Twitter we started prostate #SBRT in 2006 (one of the first to use LINACS and not CK) and first publication was 2008 https://t.co/m82F3JOuHT https://t.co/KehQi23zgs
-
-
Mashup Score: 26
MH to the prostate and pelvis with androgen deprivation therapy for men with high-risk localized prostate cancer was not significantly different than CF with regard to acute toxicity, quality of life, and oncologic efficacy. However, late grade ≥3 GI toxicity was more common in the MH arm.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
2nd RCT showing #hypoRT đźź° conv RT for high risk #ProstateCa @DrPatCheung #PHART2 RCT (PA @r_glicksman) was 1st: https://t.co/fIPFJNHBpO Now Q is the role of UHRT. Many trials accruing: @CDNCancerTrials #PR24 @VedangMurthy #PRIME @DrSuneil_PCa #PACE-NODES @NRGonc #GU013 https://t.co/Thcq5OH5jf
-
-
Mashup Score: 3
Focal boost to the MRI-specified gross tumor was well tolerated, but did not adequately improve local control. Single-fraction HDR monotherapy to 19 Gy for prostate cancer provides suboptimal local control, and should not be offered outside of clinical trials.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Should we “trademark” or reserve trial acronyms? Just saw a prostate #brachy trial called #MARS - exactly the same as we started in 2015 and published in 2019 (https://t.co/TD6MXXC0LF)
-
-
Mashup Score: 11Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial - PubMed - 6 month(s) ago
PRONOUNCE (A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease) is the first, international, randomized clinical trial to prospectively compare the cardiovascular safety of a GnRH antagonist and a GnRH agonist in …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
I’m more compelled to believe an RCT that specifically enriched for CV disease, run by a cardio-oncologist with a CV outcome as primary. How do you square Crawford’s retrospective with Lopes’ RCT @SbrtSean https://t.co/YDoITLa4tt https://t.co/eoRfd0eJFJ
-
-
Mashup Score: 5
PURPOSE Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular endothelial growth factor receptor and other kinases that improves progression-free survival in patients with metastatic RCC (mRCC). We conducted a randomized, double-blind, placebo-controlled multicenter study to test whether pazopanib would improve disease-free survival (DFS) in patients with mRCC rendered NED after metastasectomy. PATIENTS AND METHODS Patients with NED after metastasectomy were randomly assigned 1:1 to receive pazopanib 800 mg once daily versus placebo for 52 weeks. The study was designed to observe an improvement in DFS from 25% to 45% with pazopanib at 3 years, corresponding to 42% reduction in the DFS event rate. RESULTS From August 2012 to July 2017, 129 patients were enrolled. The study was unblinded after 83 DFS events (92% information). The study did not meet its primary end point. An updated an
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Not surprisingly there are no differences in toxicity (measured by admin data, prospective data coming but also negative to date) no efficacy between: Protons and Photons Yet HUGE cost difference. So why are protons still offered? https://t.co/YOjWCFXEGd https://t.co/DJmVKepTbt
-
-
Mashup Score: 11Accelerated hypofractioned postoperative radiotherapy for prostate cancer: a prospective phase I/II study - PubMed - 10 month(s) ago
We present a hypofractionated schedule of postoperative prostate radiotherapy that is both well tolerated in terms of both toxicity and quality of life measures. Initial PSA control is encouraging. Further evaluation with a longer follow-up and a larger cohort is warranted.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
We changed our postop practice during covid to 51/17 (based on #PHART4) but based on CCO funding now do 52.5/20 based on @PCaParker #RADICALS study. Who else is going further to UHF doses? Chia-Lin Tseng is leading our #PLUTO program (30/5 +- 25/5 ENI) https://t.co/SKYyGZiQ6E https://t.co/iQdHv9nQC8
-
-
Mashup Score: 11
PRONOUNCE (A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease) is the first, international, randomized clinical trial to prospectively compare the cardiovascular safety of a GnRH antagonist and a GnRH agonist in …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
I’m more compelled to believe an RCT that specifically enriched for CV disease, run by a cardio-oncologist with a CV outcome as primary. How do you square Crawford’s retrospective with Lopes’ RCT @SbrtSean https://t.co/YDoITLa4tt https://t.co/eoRfd0eJFJ
-
Agree 💯 @sandraturner49 We now cure 99% of men with localized prostate cancer (see Kennedy et al; https://t.co/CwaVKYsVvz ). The future is in preserving QOL. #SBRT lies at the heart of those gains, esp with tighter margins, adaptive RT, immobil’n, DIL dose painting + spacers https://t.co/g5AKLyxByx